欧盟HMA药品数据库（European Union HMA Authorisation of Medicines DataBase）
MR编号SE/H/0180/001
药品名称Relenza
活性成分
    • Zanamivir 5.0 mg/dose
剂型Inhalation powder, pre-dispensed
上市许可持有人GlaxoSmithKline AB, Sweden
参考成员国 - 产品名称Sweden (SE)
互认成员国 - 产品名称
    • Germany (DE)
    • Denmark (DK)
    • Belgium (BE)
    • Luxembourg (LU)
    • Iceland (IS)
    • Ireland (IE)
    • France (FR)
    • Spain (ES)
    • Italy (IT)
    • Greece (EL)
    • Norway (NO)
    • Finland (FI)
    • Poland (PL)
      Relenza
    • Latvia (LV)
      Relenza 5 mg/dose, inhalation powder, pre-dispensed
    • Lithuania (LT)
      Relenza 5 mg/dozėje inhaliacinai milteliai
    • Hungary (HU)
    • Slovak Republic (SK)
      Relenza
    • Slovenia (SI)
    • Malta (MT)
    • Portugal (PT)
    • Netherlands (NL)
    • Austria (AT)
    • Estonia (EE)
许可日期1999/06/01
最近更新日期2025/10/03
药物ATC编码
    • J05AH01 zanamivir
申请类型
  • TypeLevel1：New Active Substance
  • TypeLevel2：Initial Application
  • TypeLevel3：Full Dossier
  • TypeLevel4：Chemical Substance
  • TypeLevel5：Prescription Only
附件文件下载
市场状态Positive
©2006-2025 Drugfuture->European Union HMA Authorisation of Medicines DataBase